Pharmaceutical Technology

FEBRUARY 13, 2023

Gene therapies are an attractive way of targeting the underlying genetic mutations, but traditional approaches cannot be used while targeting mutations for Dravet Syndrome, forcing researchers to develop new ways. To tackle this, companies have developed different ways to focus on the gene.

Research 264

Research Gene Gene Therapy Genome 264

Delveinsight

SEPTEMBER 3, 2021

Thus, missed or late diagnosis is a serious concern; however, it can be due to the heterogeneity of the condition, late age of onset of symptoms, slow and gradual development of symptoms, and so on. Additionally, a lack of curative and approved therapies in the CMT disease market is a serious unmet need.

Pharma Companies 52

Pharma Companies Marketing Clinical Trials Clinical Trials 52

Drug Discovery World

JANUARY 26, 2023

DDW Editor Reece Armstrong takes a look at the pharmaceutical research and development market in 2023 and asks key opinion leaders what challenges and trends will emerge throughout the year. billion showed the pharma giant taking further steps into the oncology market and developing its speciality medicines vaccines portfolio.

Development 98

Development Drugs Clinical Trials Clinical Trials 98

pharmaphorum

DECEMBER 21, 2021

During the course of the webinar, Keefer explained how specialty sites, with deep knowledge on one or certain groups of Rare Diseases, are crucial for further progress in drug development to progress the number of treatments available to Rare Disease patients and to provide support to those individuals.

Development 92

Development Genome Genomics Drugs 92

Pharmaceutical Technology

AUGUST 4, 2022

In addition to doing more to proactively support healthcare providers and patients, digital health opportunities provide a chance for pharma companies to capture (and become a trusted source of) important real-world data about patients’ behaviour and their wider wellbeing. Breaking down the opportunities.

Pharma Companies 358

Pharma Companies Branding Production Development 358

XTalks

DECEMBER 20, 2023

As we step into 2024, the life sciences continue to evolve at an unprecedented pace, driven by technological innovation, a deeper understanding of human biology and the application of new technologies in areas like drug development and health wearables. Regulatory bodies are also taking note of the applications of AI in drug development.

Life Science 119

Life Science Gene Editing Development Clinical Trials 119

pharmaphorum

DECEMBER 6, 2022

Ben Hargreaves examines why a research project in the UK could provide key insights to develop treatments against many of the most prominent diseases impacting society. There are also hopes that clues could be found as to what risk factors are involved in the development of the most difficult to understand diseases.

Genome Project 90

Genome Project Research Genome Genomics 90

pharmaphorum

APRIL 8, 2021

COVID-19 has been a trial-by-fire showing just how quickly drugs and vaccines can be developed under the right circumstances – but there is much to do to ensure this progress is not lost, said speakers at WIRED Health 2021, including the CEOs of BioNTech and BenevolentAI. . In the UK we have world leading genetic sequencing capabilities.

Development 79

Development Drugs Vaccination Vaccine 79

World of DTC Marketing

JANUARY 24, 2022

Venture capitalists have poured $42 billion into drug development over the past three years. Most small biotech companies rely on venture capitalist funding to develop new drugs but is that a good way to go? billion, which was much lower than previous studies, which have placed the average cost of drug development as $2.8

Life Science 225

Life Science Drugs Genetic Disease Development 225

XTalks

DECEMBER 13, 2023

In 2023, biotechnology and pharmaceutical companies leverage cutting-edge technology and significant investments in research and development (R&D) to continue pushing the boundaries of innovation in the healthcare sector, transcending the challenges posed by the pandemic.

Genetics 111

Genetics Vaccination Vaccine DNA 111

Pharmaceutical Technology

MAY 24, 2023

The ability to modify or introduce genetic material in human cells in such a precise and patient-centered manner clearly constitutes a breakthrough in personalized medicine. Allogeneic therapies begin with healthy donor samples to develop the eventual therapeutic product which can be administered to multiple patients.

Clinical Trials 246

Clinical Trials Clinical Trials Gene Therapy Clinical Supply Chain 246

Drug Discovery World

JULY 19, 2023

The tide has been turning in the worlds of diagnostics and drug development. Bioinformatics and genetic sequencing are starting to be placed front and centre of public research programmes as scientists from around the world recognise the substantial benefits of knowledge sharing and resource pooling when it comes to genetic science.

Genome 52

Genome Genomics Bioinformatics Genetics 52

Cloudbyz

SEPTEMBER 25, 2020

HEPAprint, MEDIKURA, Navro, Embleema & Cloudbyz develop 5 top solutions to watch out for. Our Innovation Analysts recently looked into emerging technologies and up-and-coming startups working on solutions for the pharma sector. Clinical trials play a pivotal role in drug development. HEPAprint – Adverse Drug Reaction (ADR).

Pharma Companies 52

Pharma Companies Big Data Drugs Clinical Trials 52

World of DTC Marketing

JANUARY 1, 2022

3hree: Pharma will increase its spending in digital, but a lot of the money will be wasted. Studies show that tens of millions of dollars are being wasted due to fraud with programmatic advertising, but many pharma companies are still wasting money on the channel. Invest in product websites with content and usability studies.

Marketing 244

Marketing Doctors Doctor FDA Approval 244

pharmaphorum

FEBRUARY 16, 2021

While there have been other efforts to develop anti-inflammatory drugs for AD, targeting NLRP3 inflammasome inhibition in the brain is an innovative therapeutic approach.”. UK biotech Exscientia has signed a string of partnerships with pharma companies and other research-based organisations to apply its AI-based drug discovery platform.

Research 117

Research Drugs Protein Development 117

pharmaphorum

FEBRUARY 23, 2022

The Japanese drugmaker will get access to Code Bio’s 3DNA non-viral genetic medicine delivery platform, initially for a liver-directed programme, and is also interested in deploying the technology for central nervous system disorders.

Gene Therapy 96

Gene Therapy Gene Gene Sequencing Immune Response 96

pharmaphorum

NOVEMBER 27, 2022

A group representing pharma companies selling precision therapies for cancer has called for a change to the way genomic testing is done in Scotland, to make sure patients get access to targeted drugs. “It would have saved me and the NHS a lot of money. It would have avoided false hope.”

Genome 85

Genome Genomics Genetics Medicine 85

pharmaphorum

JULY 7, 2022

As this issue’s contributors discuss, by working together pharma companies and healthcare providers can significantly enhance oncology treatment for patients. Founder and president of clinical development analytics company Phesi Dr Gen Li discusses prominent challenges and opportunities in oncology trials.

Vaccination 52

Vaccination Vaccine Life Science Trials 52

pharmaphorum

JANUARY 10, 2022

On the back of the approvals for Pfizer/BioNTech and Moderna, suddenly there is a large amount of interest from big pharma companies to get involved in the mRNA space. The company has also stated, at the same time as the study was announced, that it will look at developing mRNA technology in oncology and genetic diseases.

RNA 99

RNA Vaccination Vaccine Pharma Companies 99

Drug Discovery World

AUGUST 3, 2023

In the first article, Troy Groetken of intellectual property and technology law firm McAndrews, Held & Malloy tells Lu Rahman how pharma companies can take this data from where it currently stands (drug design and development) to a more clinical level.

Big Data 52

Big Data Genome Genomics Pharma Companies 52

pharmaphorum

NOVEMBER 30, 2020

“NAbs are antibodies that are part of the humoral response of the adaptive immune system,” explains Rich Horgan, founder and president of Cure Rare Disease (CRD), a nonprofit biotech developing CRISPR therapeutics for Duchenne muscular dystrophy (DMD). A further issue is that patients can, and do, develop NAbs from environmental exposure.

Gene Therapy 100

Gene Therapy Gene Antibody Clinical Trials 100

pharmaphorum

MAY 4, 2022

In testing new treatments, what is promising in animal models may not transfer particularly well to humans, which helps to explain why there is a 90% failure rate during clinical development. Quris has taken its technology and used it to develop its own drug candidate pipeline.

Drugs 141

Drugs Licensing Licensing Pharma Companies 141

XTalks

AUGUST 21, 2023

This attachment halts the advancement of the genetic disorder through a reduction in the formation of fresh, abnormal bone growth. Development of medicines for rare diseases takes commitment and belief from everyone involved.

Drugs 98

Drugs FDA Approval Genetics Clinical Trials 98

pharmaphorum

FEBRUARY 17, 2021

One group excelling in this space is the Genetic Alliance. Their work ranges from developing new services in partnership with the National Health Service (NHS) to working with the All Party Parliamentary Group on Rare, Genetic and Undiagnosed Conditions, and the Department of Health on the UK Strategy for Rare Diseases.

Life Science 93

Life Science Branding Genetics Trials 93

pharmaphorum

JANUARY 18, 2022

Developing Complex, Translatable and Physiologically-Relevant Cellular Models in vitro. Explore the regulatory sciences surrounding Microphysiological systems, and their development and adoption for drug safety assessment. Workshop Leader: Wendy Rowan, Scientific Director, Novel Human Genetics, GSK. 9-10 February 2022.

In-Vitro 52

In-Vitro Engineer Drugs Pharma Companies 52

pharmaphorum

OCTOBER 18, 2022

Its aim is for patients to benefit from the treatment of others who came before, by providing data tools to drug developers and healthcare professionals. GSK has made a $70 million down payment to expand the partnership, with an undisclosed minimum financial commitment over three years that can be extended to five if desired.

Production 52

Production Clinical Trials Clinical Trials Genome 52

XTalks

DECEMBER 20, 2023

These advancements and trends addressed important industry challenges and offered opportunities to foster innovations and solutions in areas including drug development, healthcare and medical devices. Check out this article to learn about the biotech companies that went public this year.

Life Science 59

Life Science Clinical Trials Clinical Trials FDA Approval 59

World of DTC Marketing

JANUARY 31, 2021

Smaller biotechs that are developing new drugs usually don’t have the resources to take new drugs to market. The venture capitalists funding them are looking for a big payday when a pharma company acquires them.

In-Vivo 187

In-Vivo Generic Drugs Gene Therapy Drugs 187

pharmaphorum

SEPTEMBER 18, 2020

But although it was dubbed a “dangerous game”, some companies came out on top… On 6th April 1999, two companies with similar science-based cultures and a shared vision of the pharmaceutical industry came together to form what’s now considered as one of the top ten pharma companies in the world: AstraZeneca.

Pharma Companies 113

Pharma Companies Sales Vaccination Vaccine 113

pharmaphorum

MAY 26, 2022

Within pharma and healthcare, where greater representation has been proven to lead to better health outcomes for all patients and the pharmaceutical companies developing medicines, change is also happening. In recent years this has seen diversity, equity, and inclusion (DEI) become a big focus for industries to get right.

Clinical Trials 131

Clinical Trials Clinical Trials Trials Medicine 131

pharmaphorum

SEPTEMBER 7, 2022

The industry’s application of mRNA techniques during the pandemic led to the fastest vaccine development in history. The processes used are now seeing huge infrastructure commitments, in order to cement their place in the development of future products and trials. But our drug development processes are not perfect.

Clinical Trials 90

Clinical Trials Clinical Trials Trials Genetics 90

Drug Discovery World

SEPTEMBER 28, 2022

Its application in pharma, most commonly in drug discovery, has been steadily growing with global partnerships between tech vendors and pharma companies becoming more commonplace. This development is far from commercial.

Pharma Companies 52

Pharma Companies Drugs In-Vivo Genetics 52

XTalks

JANUARY 15, 2024

Personalized Medicine Driving Targeted Trials In 2022, personalized medicines accounted for 34 percent of all new FDA drug approvals, as reported by the Personalized Medicine Coalition, reflecting a robust industry focus on treatments tailored to individual genetic profiles. billion in 2022, and the trend doesn’t appear to be stalling.

Clinical Trials 105

Clinical Trials Clinical Trials Trials Clinical Research 105

pharmaphorum

APRIL 7, 2022

Novartis’ generics unit Sandoz has moved on to the next stage of a collaboration with Ares Genetics, which is focusing on the use of artificial intelligence to track antimicrobial resistance (AMR), improve diagnoses and guide the most effective use of antibiotics. “AMR, which is now estimated to directly account for nearly 1.3

Bioinformatics 52

Bioinformatics Genetics Genome Genomics 52

pharmaphorum

FEBRUARY 18, 2021

Researchers from the University of Texas Medical Branch based their findings on lab tests using SARS-CoV-2 coronaviruses that were genetically engineered to have the same mutations as those in the strain that is causing scientists so much concern.

Immune Response 52

Immune Response Genetic Engineering Vaccination Vaccine 52

Drug Discovery World

FEBRUARY 6, 2024

From finding potential active substances and identifying novel targets, to simulating how drugs will function in the human body and optimising laboratory workflows, digital technologies are having a significant impact on drug discovery and development. The company’s platform evaluated more than 11.4

Marketing 69

Marketing Medicine Genome Genomics 69

pharmaphorum

AUGUST 23, 2022

With COVID-19 vaccines and therapeutics developed in rapid time, Ben Hargreaves investigates why this has not been the case with the creation of a treatment for Long COVID. Once the scale of the threat was understood, the pharmaceutical industry reacted with a rapidity and agility that allowed vaccines to be developed at a record rate.

Vaccination 121

Vaccination Vaccine Development Trials 121